Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 13.32 Million USD | -13.88% |
| 2022 | 15.47 Million USD | -17.14% |
| 2021 | 18.67 Million USD | -20.87% |
| 2020 | 23.6 Million USD | 18.27% |
| 2019 | 19.95 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 12.73 Million USD | 0.0% |
| 2024 Q3 | 13.5 Million USD | 0.0% |
| 2024 Q2 | 14.11 Million USD | 0.0% |
| 2023 Q4 | 13.32 Million USD | -4.07% |
| 2023 FY | 13.32 Million USD | -13.88% |
| 2023 Q1 | 14.96 Million USD | -3.32% |
| 2023 Q2 | 14.43 Million USD | -3.54% |
| 2023 Q3 | 13.89 Million USD | -3.75% |
| 2022 Q3 | 19.16 Million USD | 0.48% |
| 2022 Q1 | 16.75 Million USD | -10.28% |
| 2022 FY | 15.47 Million USD | -17.14% |
| 2022 Q4 | 15.47 Million USD | -19.27% |
| 2022 Q2 | 19.07 Million USD | 13.84% |
| 2021 Q4 | 18.67 Million USD | -8.11% |
| 2021 Q2 | 21.68 Million USD | -4.19% |
| 2021 FY | 18.67 Million USD | -20.87% |
| 2021 Q3 | 20.32 Million USD | -6.29% |
| 2021 Q1 | 22.63 Million USD | -4.08% |
| 2020 Q4 | 23.6 Million USD | -1.13% |
| 2020 FY | 23.6 Million USD | 18.27% |
| 2020 Q3 | 23.86 Million USD | 12.81% |
| 2020 Q2 | 21.15 Million USD | 7.3% |
| 2020 Q1 | 19.71 Million USD | -1.19% |
| 2019 FY | 19.95 Million USD | 0.0% |
| 2019 Q2 | 20.56 Million USD | -1.4% |
| 2019 Q3 | 20.26 Million USD | -1.45% |
| 2019 Q4 | 19.95 Million USD | -1.55% |
| 2019 Q1 | 20.85 Million USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | -100.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | 26.17 Million USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 95.697% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 85.368% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 97.28% |
| Dynavax Technologies Corporation | 252.41 Million USD | 94.721% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 97.343% |
| Cosmos Health Inc. | 3.03 Million USD | -339.028% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 97.406% |
| PainReform Ltd. | 30 Thousand USD | -44320.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -2372.196% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -2372.196% |
| SCYNEXIS, Inc. | 12.15 Million USD | -9.598% |
| Safety Shot Inc | 304.9 Thousand USD | -4270.513% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -11277.199% |
| Alpha Teknova, Inc. | 13.25 Million USD | -0.566% |
| Embecta Corp. | 1.62 Billion USD | 99.18% |
| Bright Green Corporation | 201.78 Thousand USD | -6504.124% |
| Journey Medical Corporation | 14.62 Million USD | 8.863% |
| Procaps Group, S.A. | 28.41 Million USD | 53.094% |
| Theratechnologies Inc. | 51.26 Million USD | 74.004% |
| Harrow Health, Inc. | 183.17 Million USD | 92.725% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -15217.241% |
| Biofrontera Inc. | 804 Thousand USD | -1557.463% |
| DURECT Corporation | 2.7 Million USD | -393.19% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 59.857% |
| Cronos Group Inc. | 1.55 Million USD | -754.779% |
| OptiNose, Inc. | 611 Thousand USD | -2081.015% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 97.326% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 61.024% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -2828.791% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 78.062% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -4.239% |
| Radius Health, Inc. | 339.66 Million USD | 96.077% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -29.908% |
| Phibro Animal Health Corporation | 458.28 Million USD | 97.092% |
| Procaps Group S.A. | 28.41 Million USD | 53.094% |
| Alvotech | 1.02 Billion USD | 98.703% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -104.011% |
| Viatris Inc. | 16.18 Billion USD | 99.918% |
| Rockwell Medical, Inc. | 8.29 Million USD | -60.69% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -22.515% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -3866.178% |
| Tilray Brands, Inc. | 287.93 Million USD | 95.372% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 88.942% |
| Shineco, Inc. | 10.01 Million USD | -33.029% |
| PetIQ, Inc. | 437.82 Million USD | 96.956% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -6245.714% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 94.841% |
| Alimera Sciences, Inc. | 64.48 Million USD | 79.336% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 65.4% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -9764.608% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -94.331% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -1750.833% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -59168.813% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 59.322% |
| Hempacco Co., Inc. | 5.93 Million USD | -124.684% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 98.703% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 76.295% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 97.837% |
| Currenc Group, Inc. | 2.5 Million USD | -431.557% |
| Kamada Ltd. | 7.43 Million USD | -79.161% |
| Indivior PLC | 235.66 Million USD | 94.345% |
| Evoke Pharma, Inc. | 5 Million USD | -166.52% |
| Flora Growth Corp. | 942 Thousand USD | -1314.65% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -59168.813% |
| Evolus, Inc. | 120.35 Million USD | 88.928% |
| HUTCHMED (China) Limited | 48.18 Million USD | 72.346% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 97.738% |
| Akanda Corp. | 2.49 Million USD | -433.647% |